» Articles » PMID: 30626432

Increased Plasma Neurofilament Light Chain Concentration Correlates with Severity of Post-mortem Neurofibrillary Tangle Pathology and Neurodegeneration

Overview
Publisher Biomed Central
Specialty Neurology
Date 2019 Jan 11
PMID 30626432
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is pathologically characterized by the accumulation of amyloid-β (Aβ) plaques, neurofibrillary tangles and widespread neuronal loss in the brain. In recent years, blood biomarkers have emerged as a realistic prospect to highlight accumulating pathology for secondary prevention trials. Neurofilament light chain (NfL), a marker of axonal degeneration, is robustly elevated in the blood of many neurological and neurodegenerative conditions, including AD. A strong relationship with cerebrospinal fluid (CSF) NfL suggests that these biomarker modalities reflect the same pathological process. Yet, the connection between blood NfL and brain tissue pathology has not been directly compared. In this study, longitudinal plasma NfL from cognitively healthy controls (n = 12) and AD participants (n = 57) were quantified by the Simoa platform. On reaching post-mortem, neuropathological assessment was performed on all participants, with additional frozen and paraffin-embedded tissue acquired from 26 participants for further biochemical (Aβ, Aβ, tau) and histological (NfL) evaluation. Plasma NfL concentrations were significantly increased in AD and correlated with cognitive decline, independent of age. Retrospective stratification based on Braak staging revealed that baseline plasma NfL concentrations were associated with higher neurofibrillary tangle pathology at post-mortem. Longitudinal increases in plasma NfL were observed in all Braak groupings; a significant negative association, however, was found between plasma NfL at time point 1 and both its rate of change and annual percentage increase. Immunohistochemical evaluation of NfL in the medial temporal gyrus (MTG) demonstrated an inverse relationship between Braak stages and NfL staining. Importantly, a significant negative correlation was found between the plasma NfL measurement closest to death and the level of NfL staining in the MTG at post-mortem. For the first time, we demonstrate that plasma NfL associates with the severity of neurofibrillary tangle pathology and neurodegeneration in the post-mortem brain.

Citing Articles

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217.

Kovacech B, Cullen N, Novak P, Hanes J, Kontsekova E, Katina S Alzheimers Res Ther. 2024; 16(1):254.

PMID: 39580468 PMC: 11585249. DOI: 10.1186/s13195-024-01620-7.


Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring.

Petersen M, Flores-Aguilar L, Head E, Montoliu-Gaya L, Strydom A, Pape S Alzheimers Dement. 2024; 21(1):e14364.

PMID: 39535517 PMC: 11782192. DOI: 10.1002/alz.14364.


Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years.

Wicker A, Shriram J, Decourt B, Sabbagh M Neurol Ther. 2024; 13(6):1571-1595.

PMID: 39378014 PMC: 11541067. DOI: 10.1007/s40120-024-00664-z.


A framework for translating tauopathy therapeutics: Drug discovery to clinical trials.

Feldman H, Cummings J, Boxer A, Staffaroni A, Knopman D, Sukoff Rizzo S Alzheimers Dement. 2024; 20(11):8129-8152.

PMID: 39316411 PMC: 11567863. DOI: 10.1002/alz.14250.


REAL AD-Validation of a realistic screening approach for early Alzheimer's disease.

Leuzy A, Heeman F, Bosch I, Lener F, Dottori M, Quitz K Alzheimers Dement. 2024; 20(11):8172-8182.

PMID: 39311530 PMC: 11567841. DOI: 10.1002/alz.14219.


References
1.
Reiber H . Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994; 122(2):189-203. DOI: 10.1016/0022-510x(94)90298-4. View

2.
Idland A, Wyller T, Stoen R, Dahl G, Frihagen F, Braekhus A . Cerebrospinal Fluid Phosphate in Delirium after Hip Fracture. Dement Geriatr Cogn Dis Extra. 2017; 7(3):309-317. PMC: 5662974. DOI: 10.1159/000478723. View

3.
Herrmann N, Gauthier S, Lysy P . Clinical practice guidelines for severe Alzheimer's disease. Alzheimers Dement. 2009; 3(4):385-97. DOI: 10.1016/j.jalz.2007.07.007. View

4.
Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A . Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000; 54(10):1960-4. DOI: 10.1212/wnl.54.10.1960. View

5.
Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A . Plasma β-amyloid in Alzheimer's disease and vascular disease. Sci Rep. 2016; 6:26801. PMC: 4886210. DOI: 10.1038/srep26801. View